Massive trial tests RSV Shot's power to keep adults out of hospital
NCT ID NCT06684743
Summary
This large study aims to find out how well the Abrysvo RSV vaccine works at preventing hospitalizations caused by RSV in adults. It will enroll 690,000 adults aged 18 and older. Participants will be randomly assigned to either receive the vaccine or not, and researchers will track hospital records to compare outcomes.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RSV are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Center for Translational Cardiology and Pragmatic Randomized Trials Department of Cardiology Copenhagen University Hospital - Herlev and Gentofte
NOT_YET_RECRUITINGCopenhagen, 2900, Denmark
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Danske Lægers Vaccinations Service
RECRUITINGSøborg, 2860, Denmark
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
General Public Health Directorate of Galician Health Service
RECRUITINGSantiago de Compostela, A Coruña, Spain
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.